Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?

NEW YORK--(BUSINESS WIRE)--Kallyope, a clinical stage biotechnology company discovering and developing novel therapies for diseases with high unmet need, today announced that under the terms of its research collaboration with Novo Nordisk to discover novel peptide therapeutics, a ligand identified by Kallyope has been licensed by Novo Nordisk for further development, including as a potential new mechanism for the treatment of obesity. This is a significant scientific milestone stemming from the.

Kallyope Announces License Agreement with Novo Nordisk

Eli Lilly

A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company's race with Novo Nordisk to develop longer-acting insulins.

Eli Lilly's weekly insulin intensifies race with Novo Nordisk

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danish drugmaker Novo Nordisk said.

Ozempic shortages in EU will not affect all member states - Novo Nordisk

A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.

Weight-loss drugs could reduce COVID-related deaths: Study

While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly.

Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.

Novo Nordisk's Ozempic shortage expected to continue into Q4

GlaxoSmithKline

The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.

3 GLP-1 Stocks to Buy Now For Big Long-Term Gains

Vertex Pharmaceuticals

Eli Lilly is a growth machine that never runs out of opportunities. Novo Nordisk is still gaining momentum.

3 No-Brainer Stocks to Buy in September

Wegovy and Ozempic are based on the same molecule called semaglutide. An investigation into the side effects of semaglutide was just published.

This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock

Catalent

Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.

Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent

The surge in GLP-1 obesity-related research is highlighting a critical shift in medical literature, according to a recent analysis by Deutsche Bank. It notes that managing obesity is becoming increasingly vital, with terms like "diabesity"—the intersection of diabetes and obesity—gaining traction since 2023.

We've had "diabesity"; now here's what "pre-diabesity" means for Novo Nordisk, Eli Lily et al

A recent study claims that Ozempic is linked with a higher risk of suicidal thoughts than other drugs. However, other studies have reached the opposite conclusion.

Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?

HCA Healthcare

Novo Nordisk's innovative wheel is still spinning and bearing fruit in the form of strong financial results. HCA Healthcare is a leading hospital chain that continues to wrestle market share away from its peers.

2 No-Brainer Healthcare Stocks to Buy With $1,000

Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that of other drugs.

These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk

The rivalry between Novo Nordisk A/S NVO and Eli Lilly and Co LLY has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments.

Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle

There's a new twist in the ongoing debate over whether drugs widely used for weight loss are linked with thoughts of self-injury or suicide.

Ozempic and Wegovy use among patients with depression needs more scrutiny, researchers say

AstraZeneca

Johnson & Johnson

Merck

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

Novo Nordisk and Eli Lilly won't be constrained by manufacturing too much longer. That means they'll sell more of their in-demand drugs.

Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond

The recent market correction and market's overreaction to the supposedly softer Wegovy sales have triggered NVO's discounted entry points. With Ozempic/Wegovy no longer in shortage and manufacturing capacity continuing to ramp up, it is unsurprising that the management has raised their FY2024 guidance. NVO continues to report robust GLP-1, obesity, and diabetic therapy market shares in the North American and International regions as well.

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.

Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years

AbbVie

Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year

Eli Lilly is a biopharma giant that could still deliver strong growth. Novo Nordisk's growth story isn't over thanks to Ozempic, Wegovy, and a promising pipeline.

3 Fantastic Growth Stocks to Buy in August

Novo Nordisk's Pharmatech unit will build a 1.5 billion Danish crowns ($220.83 million) plant in Denmark to meet significantly higher demand for the production of medicines to fight chronic diseases, the company said on Friday.

News for Novo Nordisk Stock (NVO)